Background: NAFLD is associated with metabolic and cardiovascular disease, insulin resistance, dyslipidemia. MiR-TA1 promotes vascular inflammation, insulin resistance, obesity and fatty liver.
miR-TA1-/-/Apoe-/- mice are protected against atherosclerosis in mice.
MiR-TA1 knockout mice are protected against fatty liver (Figure 1).
We have developed a novel miR-TA1 inhibitor that protects against atherosclerosis and steatosis in the mice.
The miR-TA1 inhibitor prevents accumulation of fat in arteries and in the liver.
Treatment: In vivo inhibition of miR-TA1 using subcutaneously delivered antagomiR (direct microRNA complementary inhibitor) results in complete rescue of HFD induced NAFLD in mice and normalization of ALT (Figure 2).
